OK-432 Combined Adoptive Immunotherapy against Advanced Nasopharyngeal Carcinoma:Report of a Case Sachio Takeno 1 1Department of Otolaryngology, Hiroshima University School of Medicine pp.621-626
Published Date 1992/8/20
DOI https://doi.org/10.11477/mf.1411902685
  • Abstract
  • Look Inside

A 78-year-old male with nasopharyngeal carci-noma (NPC) was successfully treated with OK-432 combined adoptive immunotherapy. Total num-ber of 1.2×109 lymphokine activated killer (LAK) cells cultured by CDCS-1 system were return-transfered into the tumor remnant lesion after chemotherapy and radiotherapy. After admini-stration of the lymphocytes, the remaining tumor began to show remarkable reduction in size and resulted in CR status at the end of this combined therapy. Taking into consideration of the systemic failure of immunosurveillance in NPC patients generally reported before, we concluded that this combined therapy may be available for NPC treatment.

Copyright © 1992, Igaku-Shoin Ltd. All rights reserved.


電子版ISSN 1882-1316 印刷版ISSN 0914-3491 医学書院